Predictive value of 25-hydroxyvitamin D level in patients with coronary artery disease: A meta-analysis

Zhang, Hailing; Wang, Pei; Yu, Jie; Sun, Yimeng; Wang, Xiaoyan; Yang, Fan

doi:10.3389/fnut.2022.984487

Cited by 7 publications

(4 citation statements)

References 31 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, the RR was found to be 0.83 (95% CI from 0.37 to 1.86) in MACEs in patients with low Vit-D levels. All-cause mortality was also found to have an RR of 0.94 (95% CI from 0.39 to 2.26) [21]. The patient group in our study was similar to the stable coronary artery patient profile in a study in this meta-analysis.…”

supporting

confidence: 82%

Effects of Vitamin D Levels on Long-Term Coronary Events in Patients with Proven Coronary Artery Disease: Six-Year Follow-Up

Yaman,

Ceylan

2023

JCM

View full text Add to dashboard Cite

Although some clinical studies have claimed that low-dose vitamin D (Vit-D) increases the risk of long-term cardiac events, in others, no association was found. To better understand the impact of Vit-D levels on long-term cardiac events in coronary artery disease patients, this study was designed. There were 408 patients with coronary artery disease (CAD). The patients were separated into three groups based on their Vit-D levels: group 1 had levels below 10 ng/mL, group 2 had levels between 10 and 20, and group 3 had levels above 20 ng/mL. Six years were spent monitoring the patients for non-fatal MI, death, vascular revascularization, and stable course data. Mortality was found to be similar between groups (group 1: 24.5%; group 2: 13.8%; group 3: 17.4%; p > 0.05). In group 3, 47.8% of the patients did not experience any cardiac event, while 28.7% in group 2 and 27.6% in group 1 did not experience any cardiac event, and these values were found to be significant in favor of group 3 (p = 0.006). Group 3 was found to have considerably lower rates of non-ST-elevated myocardial infarction (non-STEMI) and unstable angina (UA) than the other groups did (group 1: 49%; group 2: 38%; group 3: 27%; p = 0.001). In conclusion, although vitamin D deficiency does not accompany an increase in mortality, it is associated with an increase in non-STEMI and UA in patients who have previously been diagnosed with CAD.

show abstract

supporting

confidence: 82%

Effects of Vitamin D Levels on Long-Term Coronary Events in Patients with Proven Coronary Artery Disease: Six-Year Follow-Up

Yaman,

Ceylan

2023

JCM

View full text Add to dashboard Cite

show abstract

“…High VDD was demonstrated in patients with metabolic bone disorders [ 46 ], autoimmune diseases [ 47 , 48 , 49 ], including rheumatic disorders [ 50 , 51 , 52 , 53 ], inflammatory bowel diseases [ 54 , 55 ], infectious diseases [ 56 , 57 ], endocrine system disorders (type I diabetes mellitus, thyroid diseases, etc.) [ 58 , 59 , 60 ], cardiovascular [ 61 , 62 , 63 ], nervous system disorders [ 64 , 65 , 66 ], kidney diseases [ 67 ], chronic obstructive pulmonary disease [ 68 ], and tumors [ 69 ]. Also, for patients who take some drugs on a long-term basis, a negative impact on vitamin D metabolism was observed [ 70 , 71 ].…”

Section: Consensus Recommendationsmentioning

confidence: 99%

Ukrainian Consensus on Diagnosis and Management of Vitamin D Deficiency in Adults

Grygorieva,

Tronko,

Kovalenko

et al. 2024

Nutrients

View full text Add to dashboard Cite

Vitamin D deficiency (VDD) is a global problem, however, there were no Ukrainian guidelines devoted to its screening, prevention, and treatment, which became the reason for the Consensus creation. This article aimed to present the Consensus of Ukrainian experts devoted to VDD management. Following the creation of the multidisciplinary Consensus group, consent on the formation process, drafting and fine-tuning of key recommendations, and two rounds of voting, 14 final recommendations were successfully voted upon. Despite a recent decrease in VDD prevalence in Ukraine, we recommend raising awareness regarding VDD’s importance and improving the strategies for its decline. We recommend screening the serum 25-hydroxyvitamin D (25(OH)D) level in risk groups while maintaining a target concentration of 75–125 nmol/L (30–50 ng/mL). We recommend prophylactic cholecalciferol supplementation (800–2000 IU/d for youthful healthy subjects, and 3000–5000 IU/d for subjects from the risk groups). For a VDD treatment, we recommend a short-term administration of increased doses of cholecalciferol (4000–10,000 IU/d) with 25(OH)D levels monitored after 4–12 weeks of treatment, followed by the use of maintenance doses. Additionally, we recommend assessing serum 25(OH)D levels before antiosteoporotic treatment and providing vitamin D and calcium supplementation throughout the full course of the antiosteoporotic therapy.

show abstract

“…Проте накопичено достатньо даних щодо збільшення частки ДВД в осіб старших вікових груп [1,32,35], осіб з надмірною масою тіла та метаболічним синдромом [1,32,58], темною пігментацією шкіри [59]. Крім того, продемонстровано збільшення ДВД у хворих з метаболічними захворюваннями кісткової тканини [60], осіб з інфекційною [61,62] та автоімунною патологією [63,64,65], зокрема запальними захворюваннями кишечника [66,67], ревматичною патологією [68][69][70][71] тощо, захворюваннями ендокринної системи, зокрема цукровим діабетом [72,73], гіпогонадизмом [74], патологією щитоподібної залози [75,76] тощо, захворюваннями серцево-судинної [77][78][79][80], нервової системи [81][82][83], нирок [84], онкологічними захворюваннями [85], тривалим прийомом лікарських засобів з негативним впливом на метаболізм вітаміну D [86,87], а також зв'язок зі збільшеним рівнем смертності з різних причин [88][89][90][91]. Тому визначення сироваткового рівня 25(OH)D у цієї категорії осіб може бути корисним для ефективної профілактики й лікування ДВД [15,22,…”

Section: скринінг дефіциту вітаміну D у дорослихunclassified

Diagnosis, prevention and treatment of vitamin D deficiency in adults: Ukrainian experts consensus statement

Grygorieva,

Tronko,

Kovalenko

et al. 2023

PJS

View full text Add to dashboard Cite

Background. Vitamin D deficiency (VDD) is widespread in the world; its proportion varies considerably in different populations and depends on many causes. Up to now, there were no National recommendations for the diagnosis, prevention, and treatment of VDD in adults in Ukraine. Their creation became the purpose of this work. Methodology. Consensus was created using the Delphi method, voting was conducted using the SurveyMonkey® platform. After approval of the composition of the Consensus Group, agreement on the order of formation and structure of the Consensus, creation and correction of the main statements, and two voting rounds, the main Consensus statements were formed and were successfully voted on. The 15 authors of the article are 15 experts who participated in the voting. The final 14 Consensus statements are presented in this article. Each statement is preceded by a justification based on high-quality evidence available in the current literature. Results. Despite the reduction of VDD in the Ukrainian population in recent years, experts have recommended increasing the awareness of the medical community and the Ukrainian population about the problem and ways to overcome it, with a screening of the total serum level of 25-hydroxyvitamin D (25(OH)D) in subjects from the groups of risk to achieve the target concentration of 30–50 ng/ml (75–125 nmol/l). To ensure it, we recommend the individual selection of a prophylactic dose of vitamin D (800–2000 IU/d for young healthy persons and 3000–5000 IU/d for patients with diseases and conditions that affect the metabolism of vitamin D). For the treatment of VDD, we recommend short-term intake of higher doses (4000–10,000 IU/d) of vitamin D with control of the 25(OH)D level after 4–12 weeks of treatment and subsequent use of maintenance doses. Also, we recommend the determination of serum 25(OH)D level before the initiation of antiosteoporotic therapy in patients with osteoporosis and its complications to prevent its ineffectiveness and increase the safety profile.

show abstract

Predictive value of 25-hydroxyvitamin D level in patients with coronary artery disease: A meta-analysis

Cited by 7 publications

References 31 publications

Effects of Vitamin D Levels on Long-Term Coronary Events in Patients with Proven Coronary Artery Disease: Six-Year Follow-Up

Effects of Vitamin D Levels on Long-Term Coronary Events in Patients with Proven Coronary Artery Disease: Six-Year Follow-Up

Ukrainian Consensus on Diagnosis and Management of Vitamin D Deficiency in Adults

Diagnosis, prevention and treatment of vitamin D deficiency in adults: Ukrainian experts consensus statement

Contact Info

Product

Resources

About